Nature Communications (Oct 2022)
A phase II trial of weekly nab-paclitaxel for progressive and symptomatic desmoid tumors
- Javier Martin-Broto,
- Andres Redondo,
- David S. Moura,
- Claudia Valverde,
- Jose Manuel Morales,
- Antonio Lopez-Pousa,
- Javier Martinez-Trufero,
- Antonio Gutierrez,
- Roberto Díaz-Beveridge,
- Pablo Luna,
- Virginia Martinez-Marin,
- David Marcilla,
- Ivan Arribas,
- Patricio Ledesma,
- Jose Antonio Lopez-Martin,
- Davide Di Lernia,
- Jorge Zamora,
- Nadia Hindi
Affiliations
- Javier Martin-Broto
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)
- Andres Redondo
- Department of Medical Oncology, Hospital Universitario La Paz
- David S. Moura
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)
- Claudia Valverde
- Department of Medical Oncology, Vall d’Hebron University Hospital
- Jose Manuel Morales
- Radiology Department, Virgen del Rocio University Hospital
- Antonio Lopez-Pousa
- Medical Oncology Department, Sant Pau Hospital
- Javier Martinez-Trufero
- Medical Oncology Department, Miguel Servet University Hospital
- Antonio Gutierrez
- Hematology Department, University Hospital Son Espases
- Roberto Díaz-Beveridge
- Medical Oncology Department, Hospital Universitari i Politècnic La Fe
- Pablo Luna
- Medical Oncology Department, Son Espases University Hospital
- Virginia Martinez-Marin
- Department of Medical Oncology, Hospital Universitario La Paz
- David Marcilla
- Pathology Department, Virgen del Rocio University Hospital
- Ivan Arribas
- Universitat de València
- Patricio Ledesma
- Sofpromed Investigacion Clinica SLU
- Jose Antonio Lopez-Martin
- Medical Oncology Department, 12 de Octubre University Hospital
- Davide Di Lernia
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)
- Jorge Zamora
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)
- Nadia Hindi
- Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid (IIS-FJD, UAM)
- DOI
- https://doi.org/10.1038/s41467-022-33975-6
- Journal volume & issue
-
Vol. 13,
no. 1
pp. 1 – 11
Abstract
In patients with progressive and symptomatic desmoid fibromatosis (DF) treatment with chemotherapy is typically prolonged, while surgery carries a high risk of relapse. Here, the authors report the results of a phase II clinical trial of short-course nab-paclitaxel in patients with progressive and symptomatic DF.
